Organovo Holdings, Inc. (ONVO) EPS Estimated At $-0.07 on June, 6

May 17, 2018 - By Elizabeth Jones

Organovo Holdings, Inc. (NASDAQ:ONVO) Corporate Logo
Big Money Sentiment decreased to 0.67 in Q4 2017. It has change of 0.86, from 2017Q3’s 1.53. The ratio is negative due to Organovo Holdings, Inc. positioning: 16 sold and 38 reduced. 18 funds amassed positions and 18 increased positions. Investors holded 24.05 million in 2017Q3 but now own 20.74 million shares or 13.74% less.
Tiaa Cref Inv Mngmt Ltd Liability, New York-based fund reported 228,840 shs. Ameriprise Fincl owns 142,737 shs. Money Mgmt Limited Liability Corp reported 14,900 shs stake. American Financial Gp Inc reported 0.04% stake. Bancshares Of America De owns 0% invested in Organovo Holdings, Inc. (NASDAQ:ONVO) for 29,776 shs. Royal Bank Of Canada reported 15,731 shs or 0% of all its holdings. Hightower Advisors Ltd Com accumulated 30,656 shs. Regions Fin Corporation, Alabama-based fund reported 2,000 shs. Creative Planning invested in 0% or 17,392 shs. Goldman Sachs Gru has 181,581 shs for 0% of their capital. Raymond James And Assocs, Florida-based fund reported 30,974 shs. Deltec Asset Ltd Liability Corp owns 10,000 shs for 0% of their capital. Raymond James Advsrs Inc has invested 0% of its capital in Organovo Holdings, Inc. (NASDAQ:ONVO). Paloma Mgmt has 0% invested in Organovo Holdings, Inc. (NASDAQ:ONVO). Principal Group Inc owns 15,233 shs.

Organovo Holdings, Inc. (NASDAQ:ONVO)’s earnings report is awaited on June, 6., Zacks reports. Last year’s earnings per share was $-0.1, while now analysts expect change of 30.00 % up from current $-0.07 earnings per share. Analysts at Wall Street see Organovo Holdings, Inc.’s 0.00 % EPS growth compared to $-0.07 earnings per share for previous quarter. Ticker’s shares touched $1.7 during the last trading session after 2.30% change.Organovo Holdings, Inc. has 2.45M shares volume, 167.54% up from normal. ONVO is downtrending and has moved 67.42% since May 17, 2017. ONVO underperformed by 78.97% the S&P500.

Organovo Holdings, Inc., an early commercial stage company, creates and creates functional and three-dimensional human tissues for use in medical research and therapeutic applications.The company has $188.42 million market cap. The firm develops 3D human tissue models through internal development and in collaboration with pharmaceutical, academic, and other partners.Last it reported negative earnings. The Company’s 3D human tissues could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs.

More recent Organovo Holdings, Inc. (NASDAQ:ONVO) news were announced by Globenewswire.com, Globenewswire.com and Nasdaq.com. The first one has “New Research Coverage Highlights Tyson Foods, Windstream, Laredo Petroleum, Idera Pharmaceuticals …” as a title and was announced on May 16, 2018. The next is “Organovo and Samsara Sciences Partner with New Manufacturing USA Institute” on May 03, 2018. And last was announced on May 14, 2018, called “Organovo Announces Release Date for Fiscal Fourth-Quarter 2018 Financial Results”.

Organovo Holdings, Inc. (NASDAQ:ONVO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: